Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

Kuo CY, Harrington S, Campo-Fernandez B, Wyman SK, Wu X, Zhang R, Espinoza A, de Andrade Silva BJ, Sanchez JM, Fitz-Gibbon S, Tseng CH, Pellegrini[...]

Shafiei-Jahani P, Li X, Akbari A, Haniff E, Ziprick M, Carlisle R, Goh C, Holland V, Akbari O. Hair follicle immune privilege in autoimmune and[...]

Merola JF, Childs BA, Bartley BR, Bissonnette R, Bieber T, Guttman-Yassky E, Paller AS, Simpson EL, Armstrong AW, Irvine AD. International Eczema Council Definitions of[...]